Nobel Biocare appoints Oliver Walker as Chief Financial Officer

(PresseBox) ( Zurich, Switzerland, )
Nobel Biocare announced today that Oliver Walker (43) has been appointed Chief Financial Officer and Member of the Executive Committee of Nobel Biocare. He will take up his role at the beginning of August 2012. Oliver Walker is a senior finance executive with over 17 years of experience in international industrial settings, most of which were in the medtech industry. He brings expertise in leading the finance function of companies in dynamic industries with multi-faceted business models.

Oliver Walker spent seven years as CFO of Sonova, a publicly listed, leading hearing solutions company, and four years as CFO of Stratec Medical Group. Prior to Stratec, he worked for the industrial Von Roll Group in various management positions. Oliver Walker holds a Master of Science in Business Economics from the University of Berne, Switzerland.

Richard Laube, CEO of Nobel Biocare: "Oliver Walker brings significant expertise in finance, operational leadership and building scalable organizations. His strong project management and leadership skills and experience in building medical technology companies will be a great asset to Nobel Biocare as we continue to develop our company."

Disclaimer

This media release contains forward-looking statements based on beliefs of Nobel Biocare's management. When used in this media release, words such as "anticipate", "believe", "estimate", "expect", "intend", "plan" and "project" are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@pressebox.de.